Jiangsu HengRui Medicine Co., Ltd is conducting a two-part, double-blind, randomized, placebo-controlled, and open-label phase 3 study. The purpose of this study is to investigate the efficacy, safety of Hetrombopag, another thrombopoietin-receptor agonist, in children with previously treated chronic immune thrombocytopenia between 6 and 17 years of age. In part A, patients will receive Hetrombopag for 8 weeks. In part B, all patients will receive Hetrombopag for 24 weeks.

China

https://www.clinicaltrials.gov/study/NCT04737850?cond=immune%20thrombocytopenia&term=Hetrombopag&aggFilters=status:rec&rank=1

Status: unknown